Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896296 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment Extension Study
A Phase 3 study of Opioid Use Disorder and Opioid-Related Disorders, sponsored by Indivior.
- Completed
- Registry status
- Phase 3
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT02896296 is a Phase 3 study of Opioid Use Disorder and Opioid-Related Disorders that has completed, run by Indivior. The registered enrollment target is 208 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02896296, a Phase 3 study of Opioid Use Disorder and Opioid-Related Disorders, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study is to provide ongoing treatment with RBP-6000 and safety monitoring for subjects who complete the RB-US-13-0003 study (NCT02510014) and for whom a new treatment venue has not been identified or arranged.
Conditions Studied
Interventions
- DRUG RBP-6000
Study Locations (20)
Florida
- Sarkis Clinical Trials - Gainesville
- Amit Vijapura - Jacksonville
- Meridien Research - Lakeland
- Innovative Clinical Research - Lauderhill
- Scientific Clinical Research - North Miami
California
- Collaborative Neuroscience Network - Long Beach
- Pacific Research Partners - Oakland
Louisiana
- Louisiana Research Associates - New Orleans
- Louisiana Clinical Research - Shreveport
Massachusetts
- Stanley Street Treatment and Resources - Fall River
- Adams Clinical Trials - Watertown
New Jersey
- Hassman Research Institute - Berlin
- Center for Emotional Fitness - Cherry Hill
Alabama
- Boyett Health Services - Hamilton
Arkansas
- Woodland International Research Group - Little Rock
Kansas
- Phoenix Medical Research - Prairie Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2017-08-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02896296
The ClinicalTrials.gov registry entry for NCT02896296 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (96% lower). The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which RBP-6000 is the first listed.
NCT02896296 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT02896296 about?
NCT02896296 is a clinical study titled "Open-Label Treatment Extension Study". Study is to provide ongoing treatment with RBP-6000 and safety monitoring for subjects who complete the RB-US-13-0003 study (NCT02510014) and for whom a new treatment venue has not been identified or arranged.
What is the current status of trial NCT02896296?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2016-08-17. Estimated completion is 2017-08-23.
What conditions does trial NCT02896296 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Opioid-Related Disorders.
What interventions are being tested in trial NCT02896296?
The interventions under investigation include: RBP-6000 (DRUG).
Who is sponsoring clinical trial NCT02896296?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02896296 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Buprenorphine for Individuals in Jail
RECRUITING · Phase 3
-
Standard Versus High Dose ED-Initiated Buprenorphine Induction
RECRUITING · Phase 3
-
Treating Polysubstance Use Using a Novel Digital Technology
RECRUITING · Phase 3
-
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
RECRUITING · Phase 3
-
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
RECRUITING · Phase 3
-
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.